Crossmark

Interstitial lung disease associated with systemic sclerosis (SSc-ILD)

Crossref DOI link: https://doi.org/10.1186/s12931-019-0980-7

Published Online: 2019-01-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cottin, Vincent

Brown, Kevin K.
License Information

Text and Data Mining valid from 2019-01-18
More Information

Article History

Received: 13 June 2018

Accepted: 7 January 2019

First Online: 18 January 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: Vincent Cottin has received consultancy fees from Actelion, Bayer, Boehringer Ingelheim, Galapagos, Gilead, Merck Sharp & Dohme, Novartis, Roche, Sanofi; fees for being a member of Data and Safety Monitoring Boards from Celgene, Galapagos, Promedior; and grants paid to his institution from Boehringer Ingelheim and Roche. Kevin Brown has received personal fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, Galecto, Gilead, MedImmune, Novartis, Aeolus, ProMetic, Patara, Third Pole and aTyr, as well as grants from NHLBI.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.